Figure 3.
Programmed cell death ligand 1 (PD-L1) expression levels (immunohistochemistry) in tumor cells from paired biopsies in the non-small cell lung cancer (NSCLC) and urothelial cancer dose-expansion cohorts (part B, V937+pembrolizumab). Please contact C M Rudin at rudinc@mskcc.org for access to the biomarker data presented in this figure.